Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.28−0.07 (-5.19%)
Close on Nov 20, 2026Market cap $30.47MP/E –Yield –
Kalaris Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Kalaris Therapeutics
Kalaris Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?